Alireza Shariati, Amirreza Homaei, Arya Khezrpour, Nima Azizi, Pouria Khani, Fatemeh Shariati, Maryam Rafiee, Hamed Afkhami, Mohammad Hasan Yousefi, Farzane Saeidi, Mohammad Hossein Modarressi
{"title":"CRISPR/Cas9 in cancer research and therapeutics: Clinical applications, optimization strategies, and future perspectives","authors":"Alireza Shariati, Amirreza Homaei, Arya Khezrpour, Nima Azizi, Pouria Khani, Fatemeh Shariati, Maryam Rafiee, Hamed Afkhami, Mohammad Hasan Yousefi, Farzane Saeidi, Mohammad Hossein Modarressi","doi":"10.1016/j.crbiot.2026.100382","DOIUrl":null,"url":null,"abstract":"<div><div>Genome editing tools have provided researchers and clinicians with an invaluable opportunity to understand and treat various disorders. These tools can potentially be used to precisely, efficiently, and safely treat disorders with genetic components. Among these disorders, are different malignancies. CRISPR/Cas9 has evolved to be the method of choice for most genome editing applications since it is much easier to work with. It can modify the aberrant sequence of oncogenes and tumor suppressor genes. It can also be used to design and optimize oncolytic viruses and immunotherapies with great accuracy. In the field of cancer research, it can be used to detect possible drug targets, mechanisms of drug resistance, and design cancer models such as cell lines, organoids, and even whole animals. However, the widespread application of this therapy has been limited because of its possible off-target activity and difficulties associated with its delivery to a specific site. Different approaches have been implemented to compensate for these shortcomings which are discussed in detail in this paper. With the incredible pace of progression in the field of biochemistry and data science, it will not be long before we witness the widespread application of CRISPR/Cas9 in the field of cancer therapeutics and research. Finally, a list of clinical trials applying CRISPR/Cas9 has been provided in the final section of this paper.</div></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":"12 ","pages":"Article 100382"},"PeriodicalIF":6.7000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590262826000183","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Genome editing tools have provided researchers and clinicians with an invaluable opportunity to understand and treat various disorders. These tools can potentially be used to precisely, efficiently, and safely treat disorders with genetic components. Among these disorders, are different malignancies. CRISPR/Cas9 has evolved to be the method of choice for most genome editing applications since it is much easier to work with. It can modify the aberrant sequence of oncogenes and tumor suppressor genes. It can also be used to design and optimize oncolytic viruses and immunotherapies with great accuracy. In the field of cancer research, it can be used to detect possible drug targets, mechanisms of drug resistance, and design cancer models such as cell lines, organoids, and even whole animals. However, the widespread application of this therapy has been limited because of its possible off-target activity and difficulties associated with its delivery to a specific site. Different approaches have been implemented to compensate for these shortcomings which are discussed in detail in this paper. With the incredible pace of progression in the field of biochemistry and data science, it will not be long before we witness the widespread application of CRISPR/Cas9 in the field of cancer therapeutics and research. Finally, a list of clinical trials applying CRISPR/Cas9 has been provided in the final section of this paper.
期刊介绍:
Current Research in Biotechnology (CRBIOT) is a new primary research, gold open access journal from Elsevier. CRBIOT publishes original papers, reviews, and short communications (including viewpoints and perspectives) resulting from research in biotechnology and biotech-associated disciplines.
Current Research in Biotechnology is a peer-reviewed gold open access (OA) journal and upon acceptance all articles are permanently and freely available. It is a companion to the highly regarded review journal Current Opinion in Biotechnology (2018 CiteScore 8.450) and is part of the Current Opinion and Research (CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.